---
figid: PMC7415495__nihms-1556866-f0003
figtitle: Molecular mechanisms underlying Beta-cryptoxanthin prevention of cancer
  development/progression
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC7415495
filename: nihms-1556866-f0003.jpg
figlink: /pmc/articles/PMC7415495/figure/F3/
number: F3
caption: β-Cryptoxanthin supplementation inhibits lung inflammation by reducing nuclear
  NF-κB and AP-1 and also suppresses lung cancer development by restoring RARβ, SIRT1,
  and NAChRs/PI3K/Akt pathway in lung cancer murine models; β-cryptoxanthin treatment
  regulates p73 RNA splicing, producing less oncogenic truncated ΔNP73, thereby suppressing
  proliferation and contributing to the inhibition of colon cancer in mice; β-cryptoxanthin
  increases acetylated-p53, an active form of p53, thereby inhibiting HIF-1α, LDHA,
  and increasing G6Pase and PEPCK in hepatic tumors and leading to the suppression
  of HCC in WT and BCO1/BCO2 DKO mice; β-cryptoxanthin upregulates p53 and induces
  G0/G1 cell cycle arrest and apoptosis in gastric and bladder cancer in mice. AP-1,
  activator protein 1; G6Pase, glucose-6 phosphatase; HIF-1α, hypoxia-inducible factor
  1α; LDHA, lactate dehydrogenase; MMP, matrix metallopeptidase; PEPCK, phosphoenolpyruvate
  carboxykinase; RAR, retinoic acid receptor; SIRT1, sirtuin1.
papertitle: Mechanistic understanding of β-cryptoxanthin and lycopene in cancer prevention
  in animal models.
reftext: Ji Ye Lim, et al. Biochim Biophys Acta Mol Cell Biol Lipids. ;1865(11):158652-158652.
year: '2020'
doi: 10.1016/j.bbalip.2020.158652
journal_title: Biochimica et biophysica acta. Molecular and cell biology of lipids
journal_nlm_ta: Biochim Biophys Acta Mol Cell Biol Lipids
publisher_name: ''
keywords: Carotenoids | β-cryptoxanthin | lycopene | cancer prevention | molecular
  mechanisms
automl_pathway: 0.9448636
figid_alias: PMC7415495__F3
figtype: Figure
redirect_from: /figures/PMC7415495__F3
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7415495__nihms-1556866-f0003.html
  '@type': Dataset
  description: β-Cryptoxanthin supplementation inhibits lung inflammation by reducing
    nuclear NF-κB and AP-1 and also suppresses lung cancer development by restoring
    RARβ, SIRT1, and NAChRs/PI3K/Akt pathway in lung cancer murine models; β-cryptoxanthin
    treatment regulates p73 RNA splicing, producing less oncogenic truncated ΔNP73,
    thereby suppressing proliferation and contributing to the inhibition of colon
    cancer in mice; β-cryptoxanthin increases acetylated-p53, an active form of p53,
    thereby inhibiting HIF-1α, LDHA, and increasing G6Pase and PEPCK in hepatic tumors
    and leading to the suppression of HCC in WT and BCO1/BCO2 DKO mice; β-cryptoxanthin
    upregulates p53 and induces G0/G1 cell cycle arrest and apoptosis in gastric and
    bladder cancer in mice. AP-1, activator protein 1; G6Pase, glucose-6 phosphatase;
    HIF-1α, hypoxia-inducible factor 1α; LDHA, lactate dehydrogenase; MMP, matrix
    metallopeptidase; PEPCK, phosphoenolpyruvate carboxykinase; RAR, retinoic acid
    receptor; SIRT1, sirtuin1.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - AKT1
  - AKT2
  - AKT3
  - MMP9
  - MMP2
  - SIRT1
  - RARB
  - FOS
  - FOSB
  - JUN
  - JUNB
  - JUND
  - NFKB1
  - RELA
  - RELB
  - REL
  - NFKB2
  - BCO2
  - TP73
  - ARHGAP24
  - APP
  - AAAS
  - AAA1
  - TP53
  - TP63
  - CDKN1A
  - TCEAL1
  - NSG1
  - H3P16
  - CCND1
  - HIF1A
  - BCO1
  - LINC01191
  - G6PC1
  - G6PC2
  - G6PC3
  - LDHA
  - PCK2
  - HCC
  - HYCC1
---
